AN2 Therapeutics, Inc.
ANTXHeld by 3 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying3 funds opened new positions. Short interest: 7.8% of float.
Held by 3 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying3 funds opened new positions. Short interest: 7.8% of float.
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.